Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Integ. Proteins
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.17 | 0.00 | 0.00 | 0.00 | 0.24 | 0.00 | 0.00 | 0.01 | 21.49 | 0.00 | 4.20 | 0.00 | 5.69 |
| Expenses + | 0.17 | 0.05 | 0.01 | 0.01 | 0.29 | 0.04 | 0.07 | 0.05 | 21.26 | 0.05 | 4.11 | 0.02 | 5.47 |
| Operating Profit | 0.00 | -0.05 | -0.01 | -0.01 | -0.05 | -0.04 | -0.07 | -0.04 | 0.23 | -0.05 | 0.09 | -0.02 | 0.22 |
| OPM % | 0.00% | -20.83% | -400.00% | 1.07% | 2.14% | 3.87% | |||||||
| Other Income + | 0.04 | 0.04 | 0.04 | 0.04 | 0.13 | 0.04 | 0.04 | 0.12 | 0.04 | 0.05 | 0.00 | 0.00 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Depreciation | -0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.05 | -0.02 | 0.02 | 0.02 | 0.08 | 0.00 | -0.03 | 0.08 | 0.27 | 0.00 | 0.07 | -0.02 | 0.23 |
| Tax % | 20.00% | 100.00% | 50.00% | -250.00% | 75.00% | 0.00% | 12.50% | 22.22% | 28.57% | 0.00% | 0.00% | ||
| Net Profit + | 0.04 | -0.03 | 0.01 | 0.08 | 0.02 | 0.00 | -0.03 | 0.07 | 0.21 | 0.00 | 0.05 | -0.02 | 0.23 |
| EPS in Rs | 0.11 | -0.08 | 0.03 | 0.22 | 0.05 | 0.00 | -0.08 | 0.22 | 0.66 | 0.00 | 0.03 | -0.01 | 0.12 |
Financials of Integ. Proteins
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.09 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.24 | 21.50 | 9.94 |
| Expenses + | 0.14 | 0.15 | 0.09 | 0.09 | 0.14 | 0.11 | 0.10 | 0.08 | 0.26 | 0.36 | 21.40 | 9.67 |
| Operating Profit | -0.05 | -0.07 | -0.09 | -0.09 | -0.14 | -0.11 | -0.10 | -0.08 | -0.09 | -0.12 | 0.10 | 0.27 |
| OPM % | -55.56% | -87.50% | -52.94% | -50.00% | 0.47% | 2.72% | ||||||
| Other Income + | 0.17 | 0.18 | 0.20 | 0.18 | 0.17 | 0.16 | 0.16 | 0.16 | 0.16 | 0.25 | 0.23 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 |
| Profit before tax | 0.09 | 0.08 | 0.08 | 0.06 | 0.00 | 0.02 | 0.03 | 0.05 | 0.04 | 0.10 | 0.32 | 0.28 |
| Tax % | 0.00% | 0.00% | 50.00% | 83.33% | 50.00% | 33.33% | 40.00% | 25.00% | 10.00% | 21.88% | 21.43% | |
| Net Profit + | 0.09 | 0.08 | 0.05 | 0.01 | 0.02 | 0.01 | 0.02 | 0.04 | 0.03 | 0.09 | 0.25 | 0.23 |
| EPS in Rs | 0.24 | 0.22 | 0.14 | 0.03 | 0.05 | 0.03 | 0.05 | 0.11 | 0.08 | 0.24 | 0.78 | 0.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Integ. Proteins
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 | 19.03 |
| Reserves | -1.12 | -1.03 | -0.98 | -0.98 | -1.09 | -1.09 | -1.07 | -1.03 | -1.00 | -0.91 | 16.60 | 1.50 |
| Borrowings + | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | 0.19 | 0.04 | 3.90 | 0.00 |
| Other Liabilities + | 0.16 | 0.18 | 0.05 | 0.10 | 0.13 | 0.12 | 0.13 | 0.12 | 0.10 | 0.08 | 8.35 | 0.08 |
| Total Liabilities | 2.56 | 2.67 | 2.59 | 2.64 | 2.56 | 2.55 | 2.61 | 2.69 | 2.81 | 2.73 | 32.37 | 20.61 |
| Fixed Assets + | 0.64 | 0.61 | 0.58 | 0.55 | 0.52 | 0.49 | 0.47 | 0.44 | 0.41 | 0.42 | 0.05 | 0.05 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.10 | 0.10 | 0.15 | 0.00 | 0.00 |
| Other Assets + | 1.91 | 2.06 | 2.01 | 2.09 | 2.04 | 2.06 | 2.03 | 2.15 | 2.30 | 2.16 | 32.32 | 20.56 |
| Total Assets | 2.56 | 2.67 | 2.59 | 2.64 | 2.56 | 2.55 | 2.61 | 2.69 | 2.81 | 2.73 | 32.37 | 20.61 |
Financials of Integ. Proteins
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -0.07 | -0.08 | -0.21 | -0.24 | 0.14 | -0.16 | -0.09 | -0.09 | -0.12 | -0.06 | -23.56 | 3.60 |
| Cash from Investing Activity + | 0.08 | 0.18 | 0.18 | 0.18 | 0.02 | 0.03 | 0.02 | 0.01 | 0.00 | 0.34 | 2.47 | 0.00 |
| Cash from Financing Activity + | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 | 0.00 | 0.03 | 0.05 | 0.11 | 0.16 | 21.12 | -3.71 |
| Net Cash Flow | 0.01 | 0.10 | -0.02 | -0.07 | 0.08 | -0.13 | -0.03 | -0.04 | -0.01 | 0.43 | 0.03 | -0.10 |
| Free Cash Flow | -0.07 | -0.08 | -0.21 | -0.24 | 0.14 | -0.16 | -0.09 | -0.09 | -0.12 | -0.02 | -23.13 | 3.60 |
| CFO/OP | 140% | 114% | 233% | 256% | -100% | 127% | 100% | 88% | 111% | 33% | -23,480% | 1,356% |
Financials of Integ. Proteins
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 136.88 | 0.00 | 0.00 | 0.00 | 75.64 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 136.88 | 0.00 | 0.00 | 0.00 | 75.64 | ||||||
| Working Capital Days | -608.33 | -730.00 | -85.88 | -60.83 | 339.20 | 752.77 | ||||||
| ROCE % | 3.81% | 3.27% | 3.18% | 2.36% | 0.00% | 0.82% | 1.22% | 1.98% | 1.52% | 0.37% | 1.87% | 1.26% |
If you can provide a valid transcript or document, I will be happy to assist with your query. Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q4…
The provided PDF page contains a "500 . Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q3 FY23 earnings call — and how it ranks against sector…
Management is optimistic about sustaining EBITDA margins (12-14%) with profitable business mix. Key concall takeaways from Chamanlal Setia's Q1 FY27 earnings…
100 crores revenue in vegetables within 3 to 5 years. Key concall takeaways from Kaveri Seed Company Ltd's Q1 FY27 earnings call — and how it ranks against…